Chandigarh: antiviral drug It was first confirmed to be effective against influenza, COVID-19 and swine flu variants, tested in Mohali, Chandigarh, Lopal and Bengaluru.
Eiser (Indian Institute of Science Education and Research), Imtech (Institute of Microbiology Technology), IIT (Indian Institute of Technology), Indian Institute of Science (IISc) published research results in an international journal pros pathogen. To make antiviral drugs work, researchers have taken a novel approach that targets host cells rather than attacking viruses directly.
Traditional antiviral research has targeted viruses with drugs called “.direct-acting antiviral drugsAll current FDA-approved antiviral drugs in clinical use against COVID-19 and influenza, despite several studies reporting new virus strains that can evade the drugs. , is of this kind. SARS-CoV-2 and influenza virus It evolves rapidly and becomes resistant to direct attacks. This makes treatment of new outbreaks difficult.
Indranil Banerjee, Ph.D., Department of Biological Sciences, IISER-Mohali said: “To address this problem of antiviral resistance, we used a novel host-directed therapy that attacks the cells the virus needs to enter to establish infection. There are no FDA-approved host-directed drugs for influenza or influenza.Because viruses are not motile, they use host cell machinery to gain entry into cells.We have compounds that block entry points. We have discovered a class of .We call these compounds diphenyl urea derivatives or DPUDs.”
The research team identified five DPUDs that could block both SARS-CoV-2 and influenza viruses by 95-100 percent. These are Wuhan, Delta, Omicron stocks of COVID The H1N1 and H3N2 strains of swine flu do not induce any resistance to these viruses.Other contributors to this research were Dr. Prabal Banerjee of IIT-Ropar, Dr. Krishan Gopal of Imtech, and Dr. Raghavan Varadharajan IISc-Bangalore.